| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/16/2002 | EP1171600A2 Zalpha13: a human secreted protein |
| 01/16/2002 | EP1171596A1 Synthetic transmembrane components |
| 01/16/2002 | EP1171595A1 13 transmembrane protein expressed in prostate cancer |
| 01/16/2002 | EP1171591A1 48 human secreted proteins |
| 01/16/2002 | EP1171590A1 50 human secreted proteins |
| 01/16/2002 | EP1171587A1 Peptide from antigen muc-1 for triggering an immune response to tumor cells |
| 01/16/2002 | EP1171586A2 Methods and compositions for inhibiting the function of polynucleotide sequences |
| 01/16/2002 | EP1171585A1 49 human secreted proteins |
| 01/16/2002 | EP1171580A2 Human homologues of fused gene |
| 01/16/2002 | EP1171579A1 Human tumor necrosis factor receptor tr9 |
| 01/16/2002 | EP1171578A2 Pharmaceutical composition comprising pim-activated nkt cells, and therapeutic use thereof |
| 01/16/2002 | EP1171573A1 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 01/16/2002 | EP1171469A1 ANTI-p53 ANTIBODIES |
| 01/16/2002 | EP1171468A2 Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment |
| 01/16/2002 | EP1171464A2 Peptide homodimers or peptide heterodimers derived from interleukin 12 |
| 01/16/2002 | EP1171463A2 Peptide homodimers and peptide heterodimers, derived from interferon alpha 2 |
| 01/16/2002 | EP1171462A2 49 human secreted proteins |
| 01/16/2002 | EP1171460A1 48 human secreted proteins |
| 01/16/2002 | EP1171457A1 46 human secreted proteins |
| 01/16/2002 | EP1171456A1 50 human secreted proteins |
| 01/16/2002 | EP1171444A1 Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines |
| 01/16/2002 | EP1171442A1 Xanthine derivatives and analogs as cell signalling inhibitors |
| 01/16/2002 | EP1171440A1 Substituted-3-cyano-[1.7],[1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases |
| 01/16/2002 | EP1171435A2 Pyrimidine-2-one derivatives as integrin receptor ligands |
| 01/16/2002 | EP1171424A1 Cyclo-alkyl substituted benzimidazoles and their use as parp inhibitors |
| 01/16/2002 | EP1171422A1 Mmp inhibitor |
| 01/16/2002 | EP1171162A2 Cobalamin conjugates useful as antitumor agents |
| 01/16/2002 | EP1171151A1 Thrombospondin-2 and uses thereof |
| 01/16/2002 | EP1171149A1 Inhibition of proteasome function induces programmed cell death in endothelial cells |
| 01/16/2002 | EP1171144A1 Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa |
| 01/16/2002 | EP1171143A1 Peptide extract of lupine and pharmaceutical or cosmetic or nutritional composition comprising same |
| 01/16/2002 | EP1171142A1 Inflammatory mediation obtained from atractylodes lancea |
| 01/16/2002 | EP1171141A1 MEDICAMENT FOR INHIBITING NF-kB |
| 01/16/2002 | EP1171135A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/16/2002 | EP1171128A1 Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy |
| 01/16/2002 | EP1171127A2 Pharmaceutical compositions containing pyridine or pyrimidine derivatives for inhibition of cytokine production and secretion |
| 01/16/2002 | EP1171125A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/16/2002 | EP1171118A2 Methods and compositions for enhancing delivery of therapeutic agents to tissues |
| 01/16/2002 | EP1171113A1 Compounds useful as phosphotyrosine mimics |
| 01/16/2002 | EP1171106A1 Treatment of certain cancers associated with weight gain |
| 01/16/2002 | EP1171100A1 Solubilized pharmaceutical composition for parenteral administration |
| 01/16/2002 | EP0880517B1 Quinazoline compounds |
| 01/16/2002 | EP0840791B1 Generation of immune responses to prostate-specific antigen (psa) |
| 01/16/2002 | EP0832073B1 Quinazolines and pharmaceutical compositions |
| 01/16/2002 | EP0817859B1 Recombinant dna vectors for gene therapy |
| 01/16/2002 | EP0697875B1 Use of modified tall-104 cells to treat cancer and viral diseases |
| 01/16/2002 | EP0680964B1 PYRROLO [3,2-e]INDOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE |
| 01/16/2002 | EP0672681B1 Novel antitumor peptide |
| 01/16/2002 | EP0672180B1 Oligonucleotide modulation of protein kinase c |
| 01/16/2002 | CN1331801A Kidney disease detection and treatment |
| 01/16/2002 | CN1331797A High energy phototherapeutic agents |
| 01/16/2002 | CN1331701A Modified peptides as therapeutic agents |
| 01/16/2002 | CN1331693A 1,2-annelated quinoline derivatives |
| 01/16/2002 | CN1331683A 2-phenylbenzimidazoles and 2-phenylindoles, and prodn. and use thereof |
| 01/16/2002 | CN1331682A Substituted 2-phenylbenzimidazoles, prodn. thereof and their use |
| 01/16/2002 | CN1331680A N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors |
| 01/16/2002 | CN1331674A Sulfonamide hydroxamates |
| 01/16/2002 | CN1331599A Compounds and their therapeutic use with diabetic complications |
| 01/16/2002 | CN1331598A Medicinal compsns. for treating osseous lesion in multiple myeloma |
| 01/16/2002 | CN1331597A Use of bisphosphonates for prevention and treatment of infectious processes |
| 01/16/2002 | CN1331590A Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating disease associated with increase of AT-1 or AT-2 receptors |
| 01/16/2002 | CN1331308A Polypeptide-human I kappa B kinase 15 and polynucleotide for coding it |
| 01/16/2002 | CN1331218A Polypeptide-human zinc finger protein 12.98 and polynucleotide for coding it |
| 01/16/2002 | CN1331217A Polypeptide-human EHD protein 9.57 and polynucleotide for coding it |
| 01/16/2002 | CN1331174A Polypeptide-human Zinc finger protein 10.45 and polynucleotide for coding it |
| 01/16/2002 | CN1331163A Polypeptide-human transcription regulator factor 2FM1 isomer 19.47 and polynucleotide for coding it |
| 01/16/2002 | CN1331159A Polypeptide-human mitochondrial cadherin 10.12 and polynucleotide for coding it |
| 01/16/2002 | CN1331119A Polypeptide-human FK506 bindin 13.42 and polynucleotide for coding it |
| 01/16/2002 | CN1330946A Process for preparing garlic injection |
| 01/16/2002 | CN1330925A Instant bee pollen and its preparing process |
| 01/16/2002 | CN1077887C Method for preparing antihypertensive and anticancer compound |
| 01/16/2002 | CN1077886C Amidino derivatives useful as nitric oxide synthase inhibitors |
| 01/16/2002 | CN1077801C Carcinoembryonic antigen gene engineering antibody CL-3-scFv |
| 01/16/2002 | CN1077797C Chinese medicine powder for curing leukemia |
| 01/15/2002 | US6339160 For therapy of tumoral growth and metastatization, aterosclerosis, multiple sclerosis, alzheimer's disease, osteoporosis, hypertension, rheumatoid arthritis and other inflammatory diseases |
| 01/15/2002 | US6339151 Forming compounds using a nucleic acid base with a phosphorous halide to form drugs for nonproliferation of cells |
| 01/15/2002 | US6339149 Isolated nucleic acid molecules which encode tumor rejection antigens found in dage |
| 01/15/2002 | US6339139 Receptor-mediated gene transfer system for targeting tumor gene therapy |
| 01/15/2002 | US6339107 Methods for treatment of Emphysema using 13-cis retinoic acid |
| 01/15/2002 | US6339098 2,1-benzisothiazoline 2,2-dioxides |
| 01/15/2002 | US6339092 Metalloprotease inhibitors |
| 01/15/2002 | US6339085 For therapy of hypertrophy, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, heart failure subsequent to myocardial infarction, myocardial infarction, ischemia reperfusion injury, blood coagulation |
| 01/15/2002 | US6339083 Multiheterocyclic pharmAceuticals |
| 01/15/2002 | US6339079 Steroid sulfamates, method for the production and use thereof |
| 01/15/2002 | US6339073 Uses of nicotinamide adenine dinucleotide and its derivatives for treatment of malignant and infectious diseases |
| 01/15/2002 | US6339071 For preventing proliferation of tumor cells |
| 01/15/2002 | US6339070 Gene directed enzyme prodrug therapy (gdept) using in situ antibody generation to provide enhanced selectivity, in cancer therapy; for delivering cytotoxic drugs |
| 01/15/2002 | US6339069 Administering formulation comprising pharmaceutically acceptable carrier; and, liposome comprising a bioactive agent and a lipid component, the lipid component comprising a peptide-lipid conjugate |
| 01/15/2002 | US6339065 Episomal expression vector for human gene therapy |
| 01/15/2002 | US6338953 Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein |
| 01/15/2002 | US6338859 Polymeric micelle compositions |
| 01/15/2002 | US6338853 Cell surface antigens from human cancer and cultures |
| 01/15/2002 | US6338845 Tumor killing effects of enterotoxins, superantigens, and related compounds |
| 01/15/2002 | US6338843 Polysaccharide dextrin bonded to doxorubicin |
| 01/15/2002 | CA2109304C Glycosylated prodrugs, and their processes of preparation and use |
| 01/15/2002 | CA2001719C Phosphorylated fusion proteins and uses related thereto |
| 01/13/2002 | CA2312051A1 Methylated nucleotide regulation of gene expression |
| 01/10/2002 | WO2002003071A2 Modulators of trk protein activity, compositions and uses |
| 01/10/2002 | WO2002002781A1 Heterodimeric fusion proteins |
| 01/10/2002 | WO2002002780A2 Human serine-threonine kinase |